Collegium Pharmaceutical (COLL) Net Cash Flow Growth (1y) (2015 - 2026)
Powered by 
Analysis
Collegium Pharmaceutical (COLL) Net Cash Flow Growth (1y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 93.66% |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | -323.06% |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 248.11% |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | 195.58% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -517.34% |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | -88.52% |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 3,465.10% |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 270.63% |
| 10 | Collegium Pharmaceutical | 753.09 Mn | 603.77 Mn | 110.29 Mn | -757.93% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -757.93% |
| Mar 31, 2026 | 82.59% |
| Dec 31, 2025 | 156.79% |
| Sep 30, 2025 | 130.07% |
| Jun 30, 2025 | 137.97% |
| Mar 31, 2025 | 298.14% |
| Dec 31, 2024 | 261.37% |
| Sep 30, 2024 | -331.99% |
| Jun 30, 2024 | -536.34% |
| Mar 31, 2024 | -110.79% |
| Dec 31, 2023 | -149.50% |
| Sep 30, 2023 | -321.12% |
| Jun 30, 2023 | -20.31% |
| Mar 31, 2023 | 220.15% |
| Dec 31, 2022 | 680.51% |
| Sep 30, 2022 | 219.66% |
| Jun 30, 2022 | -19.80% |
| Mar 31, 2022 | -1,019.16% |
| Dec 31, 2021 | -178.40% |
| Sep 30, 2021 | -148.27% |